Type 1 diabetes genome-wide association studies: Not to be lost in translation

Research output: Contribution to journal › Review › Research › peer-review

Standard

Type 1 diabetes genome-wide association studies : Not to be lost in translation. / Pociot, Flemming.

In: Clinical and Translational Immunology, Vol. 6, No. 12, e162, 12.2017.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Pociot, F 2017, 'Type 1 diabetes genome-wide association studies: Not to be lost in translation', Clinical and Translational Immunology, vol. 6, no. 12, e162. https://doi.org/10.1038/cti.2017.51

APA

Pociot, F. (2017). Type 1 diabetes genome-wide association studies: Not to be lost in translation. Clinical and Translational Immunology, 6(12), [e162]. https://doi.org/10.1038/cti.2017.51

Vancouver

Pociot F. Type 1 diabetes genome-wide association studies: Not to be lost in translation. Clinical and Translational Immunology. 2017 Dec;6(12). e162. https://doi.org/10.1038/cti.2017.51

Author

Pociot, Flemming. / Type 1 diabetes genome-wide association studies : Not to be lost in translation. In: Clinical and Translational Immunology. 2017 ; Vol. 6, No. 12.

Bibtex

@article{c5095379fd594a878cbbf5c0aec8d791,
title = "Type 1 diabetes genome-wide association studies: Not to be lost in translation",
abstract = "Genetic studies have identified >60 loci associated with the risk of developing type 1 diabetes (T1D). The vast majority of these are identified by genome-wide association studies (GWAS) using large case-control cohorts of European ancestry. More than 80% of the heritability of T1D can be explained by GWAS data in this population group. However, with few exceptions, their individual contribution to T1D risk is low and understanding their function in disease biology remains a huge challenge. GWAS on its own does not inform us in detail on disease mechanisms, but the combination of GWAS data with other omics-data is beginning to advance our understanding of T1D etiology and pathogenesis. Current knowledge supports the notion that genetic variation in both pancreatic β cells and in immune cells is central in mediating T1D risk. Advances, perspectives and limitations of GWAS are discussed in this review.",
author = "Flemming Pociot",
year = "2017",
month = dec,
doi = "10.1038/cti.2017.51",
language = "English",
volume = "6",
journal = "Clinical and Translational Immunology",
issn = "2050-0068",
publisher = "Nature Publishing Group",
number = "12",

}

RIS

TY - JOUR

T1 - Type 1 diabetes genome-wide association studies

T2 - Not to be lost in translation

AU - Pociot, Flemming

PY - 2017/12

Y1 - 2017/12

N2 - Genetic studies have identified >60 loci associated with the risk of developing type 1 diabetes (T1D). The vast majority of these are identified by genome-wide association studies (GWAS) using large case-control cohorts of European ancestry. More than 80% of the heritability of T1D can be explained by GWAS data in this population group. However, with few exceptions, their individual contribution to T1D risk is low and understanding their function in disease biology remains a huge challenge. GWAS on its own does not inform us in detail on disease mechanisms, but the combination of GWAS data with other omics-data is beginning to advance our understanding of T1D etiology and pathogenesis. Current knowledge supports the notion that genetic variation in both pancreatic β cells and in immune cells is central in mediating T1D risk. Advances, perspectives and limitations of GWAS are discussed in this review.

AB - Genetic studies have identified >60 loci associated with the risk of developing type 1 diabetes (T1D). The vast majority of these are identified by genome-wide association studies (GWAS) using large case-control cohorts of European ancestry. More than 80% of the heritability of T1D can be explained by GWAS data in this population group. However, with few exceptions, their individual contribution to T1D risk is low and understanding their function in disease biology remains a huge challenge. GWAS on its own does not inform us in detail on disease mechanisms, but the combination of GWAS data with other omics-data is beginning to advance our understanding of T1D etiology and pathogenesis. Current knowledge supports the notion that genetic variation in both pancreatic β cells and in immune cells is central in mediating T1D risk. Advances, perspectives and limitations of GWAS are discussed in this review.

U2 - 10.1038/cti.2017.51

DO - 10.1038/cti.2017.51

M3 - Review

C2 - 29333267

AN - SCOPUS:85044123431

VL - 6

JO - Clinical and Translational Immunology

JF - Clinical and Translational Immunology

SN - 2050-0068

IS - 12

M1 - e162

ER -

ID: 196139547